Browse the evidence

Mitochondrial uncoupling promotes energy dissipation and may serve as a strategy for obesity treatment.

Practitioners may consider mitochondrial uncoupling as a potential target for obesity interventions.

Metabolic drugs such as GLP-1-based therapies and SGLT2 inhibitors have benefits that extend beyond metabolic improvements into changes in chronic inflammation.

Practitioners should consider the anti-inflammatory potential of metabolic drugs in clinical settings.

The review discusses emerging therapeutic strategies for MASLD and its associated comorbidities.

Practitioners should stay informed about new treatment options for MASLD and its comorbidities.

Pharmacological classes of metabolic drugs have unexpected and often beneficial effects on cardiovascular outcomes.

Consider the use of metabolic drugs in managing cardiovascular health.

A maladaptive adipokine milieu is associated with endothelial dysfunction, myocardial stiffening, and muscle atrophy in HFpEF.

Recognizing this cycle can inform targeted interventions.

Small molecule agonists of GLP-1 receptor have advantages of low cost and oral administration compared to peptide drugs.

Practitioners may consider small molecule GLP-1 receptor agonists as a cost-effective and convenient treatment option.

High fat feeding increases mTORC 1/2 complex formation by approximately 70% for Raptor and 60% for Rictor.

High fat diets significantly alter mTOR complex formation, which may impact muscle growth and metabolism.

Exercise training prevents the activation of S6K1 and the serine phosphorylation of IRS1 induced by a high-fat diet.

Incorporating exercise can mitigate negative metabolic effects of high-fat diets.

Insulin stimulated S473 phosphorylation of Akt1 was increased by approximately 25% in a high-fat diet.

High-fat diets can enhance insulin signaling through Akt1, which may have implications for metabolic health.

Higher Genetic Risk Score (GRS) relates to smaller year one change in waist circumference adjusted for body mass index (WCadjBMI) in lifestyle intervention arms.

Practitioners should consider genetic risk factors when designing weight loss interventions, as they may influence outcomes.

Each weighted risk allele in the GRS contributes to a 0.06 cm higher waist circumference at year 1 for individuals with an initial BMI of 34 and a year 1 reduction in BMI of 2.5.

Understanding the genetic contribution to waist circumference can help tailor interventions for individuals.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Emerging mechanisms of obesity-related vascular dysfunction include skeletal muscle inflammation and signals from the gut microbiome.

Practitioners should consider these emerging mechanisms when developing treatment strategies for obesity-related vascular issues.

Recent progress in glucose-responsive systems enables real-time, glucose-triggered therapeutic activation.

This technology could lead to more effective and responsive diabetes treatments.

Recent advancements in anti-obesity drugs allow for genotype-informed treatment options.

Practitioners can utilize genetic information to tailor obesity treatments.

One standard deviation higher polygenic score (PS) related to smaller one-year change in waist circumference adjusted for body mass index (WCadjBMI) in the lifestyle intervention arms at year 1, predicting poorer response among White participants overall.

Practitioners should consider genetic factors when assessing weight loss responses to lifestyle interventions.

Participants assigned a plant-based diet for phase 1 did not see an increase in TMAO during their subsequent animal-meat phase.

Dietary sequencing may influence TMAO levels and cardiovascular risk.

Around 50 significant metabolites and 12 significant microbiota genera correlated with TMAO.

Understanding these correlations may help in developing targeted therapies for CVD prevention.

Prostaglandin E2 (PGE2) production was reduced in both CR groups, significantly in the 30% CR group.

Reducing PGE2 through calorie restriction may enhance T cell function.

Hypercalciuria in patients is significantly associated with hypertension (OR = 2.9, 1.4-6.2) and kidney stone disease (KSD) (OR = 1.9, 1.03-3.5) in first-degree relatives, particularly siblings.

Clinicians should consider hypercalciuria as a risk factor for hypertension and KSD in patients' families.

Low urinary potassium excretion in hypercalciuric patients predicts hypertension (OR = 3.3, 1.5-7.4) and KSD (OR = 2.9, 1.1-7.3) in first-degree relatives.

Monitoring potassium intake may be important for assessing hypertension and KSD risk in families of hypercalciuric patients.

Adipositas is influenced by environmental factors and genetic variants.

Understanding the dual influence of genetics and environment can guide obesity treatment strategies.

Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.

The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.

Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.

Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.